Heat-treated Lactiplantibacillus plantarum nF1 (HT-nF1) increases immune cell activation and the production of various immunomodulators (e.g., interleukin (IL)-12) as well as immunoglobulin (Ig) G, which plays an important role in humoral immunity, and IgA, which activates mucosal immunity. To determine the effect of HT-nF1 intake on improving immune function, a randomized, double-blind, placebo-controlled study was conducted on 100 subjects with normal white blood cell counts. The HT-nF1 group was administered capsules containing 5 × 10¹¹ cells of HT-nF1 once a day for 8 weeks. After 8 weeks of HT-nF1 intake, significant changes in IL-12 were observed in the HT-nF1 group (p = 0.045). In particular, the change in natural killer (NK) cell activity significantly increased in subjects with low secretory (s) IgA (≤49.61 μg/mL) and low NK activity (E:T = 10:1) (≤3.59%). These results suggest that HT-nF1 has no safety issues and improves the innate immune function by regulating T helper (Th)1-related immune factors. Therefore, we confirmed that HT-nF1 not only has a positive effect on regulating the body’s immunity, but it is also a safe material for the human body, which confirms its potential as a functional health food ingredient.

Objectives: This study aims to evaluate the efficacy and safety of probiotics for body fat reduction in obese individuals. Methods: A total of 106 participants with a body mass index between 25 and 30 kg/m² were randomly assigned to either the experimental group treating with Lactobacillus plantarum LMT1-48 or the placebo group in the placebo-controlled clinical trial. Body composition was assessed by dual-energy X-ray absorptiometry and computed tomography. Fecal samples between the groups were contrasted via DNA sequencing for evaluation of the microbiota and its diversity. Results: After 12 weeks of follow-up period, the body fat mass decreased significantly, from 30.0 ± 4.4 to 28.3 ± 4.1 kg in the experimental group (p = 0.009). The percentage of body fat in the two groups showed a similar trend (p = 0.004). Conclusions: LMT1-48 also positively influenced the microbial taxa linked to obesity analyzed by gut microbiome sequencing. LMT1-48 is a safe and collaborative agent to reduce obesity.

Matrix metalloproteinase-1 (MMP-1) is a zinc-containing endopeptidase that degrades dermal collagen and other extracellular matrix molecules. It is recognized as one of the most important indicators of cellular senescence and age-related skin changes. Here, we introduced a novel MMP-1 peptide nucleic acid (PNA) derivative—PNA-20 carboxyethyl fluorene (CEF)—which can interact with and consequently silence the MMP-1 gene sequence. The investigation on the efficacy of PNA-20 CEF in MMP-1 silencing in human dermal fibroblasts revealed significantly decreased expression of MMP-1 at both gene and protein levels. Treatment with PNA-20 CEF showed significantly increased expression of collagen I protein, indicating its potential role in preventing the degradation of collagen I and consequently combating the skin aging process. Its topical application on 3D human skin tissue showed successful absorption into the epidermis and the upper dermis. Furthermore, the additional 4-week single-arm prospective study on 21 Asian women revealed improvements in facial wrinkles, skin moisture, elasticity, and density after the use of the topical PNA-20 CEF cosmeceutical formulation. Additional in-vitro and ex-vivo studies are needed for a comprehensive understanding of the skin anti-aging effects of MMP-1 PNA.

Probiotics offer a non-pharmacological approach to support immune function, yet clinical evidence for strain-specific benefits remains limited. We conducted an 8-week, randomized, double-blind, placebo-controlled trial of Lacticaseibacillus rhamnosus LM1019 in 121 generally healthy adults. Both the active and placebo arms produced comparable within-group increases in natural killer (NK) cell cytotoxicity and modest, non-differential declines in circulating cytokines; safety and tolerability were excellent, with mild adverse events evenly distributed. In a post-hoc subgroup defined by age ≥ 40 years, baseline white blood cell count ≥ 5.0 × 10³/µL, and LDL cholesterol < 130 mg/dL, the probiotic arm demonstrated statistically significant enhancements in NK activity (p = 0.021–0.008 across all effector-to-target ratios), whereas no change was observed in the placebo group. These findings suggest that this intervention may selectively boost NK-mediated immunity in individuals with preserved baseline immune and lipid profiles. Future larger trials using phenotype-driven enrollment and controlled dietary intake are warranted to confirm and extend these results.